The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study
Authors
Keywords
CIN, HPV16, Immunotherapy, Vaccination, Memory response
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 63, Issue 2, Pages 147-160
Publisher
Springer Nature
Online
2013-11-14
DOI
10.1007/s00262-013-1499-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
- (2013) Mariette I E van Poelgeest et al. Journal of Translational Medicine
- A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
- (2012) Peggy J. de Vos van Steenwijk et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial
- (2012) Eliane C.M. Zeestraten et al. INTERNATIONAL JOURNAL OF CANCER
- Therapeutic vaccination against human papilloma virus induced malignancies
- (2011) Sjoerd H van der Burg et al. CURRENT OPINION IN IMMUNOLOGY
- A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
- (2011) Kazuhiro Kakimi et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
- (2010) S Daayana et al. BRITISH JOURNAL OF CANCER
- Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
- (2010) C. M. Britten et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
- (2010) Miho Kaida et al. JOURNAL OF IMMUNOTHERAPY
- Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
- (2010) Barney S. Graham et al. PLoS One
- Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
- (2010) M. J. P. Welters et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- “MIATA”—Minimal Information about T Cell Assays
- (2009) Sylvia Janetzki et al. IMMUNITY
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
- (2009) Gemma G. Kenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine
- (2008) M. J.P. Welters et al. CLINICAL CANCER RESEARCH
- Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
- (2008) G. G. Kenter et al. CLINICAL CANCER RESEARCH
- Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
- (2008) Yimin Wu et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search